Endocrine Abstracts

Background: Immune checkpoint inhibitors (ICIs) are a novel group of drugs, used for treatment of various types of malignancies. The receptors cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) or its ligand (PDL-1) are targeted by those inhibitors. They are associated with immune-related adverse events (irAEs). Endocrinopathies are the most frequent irAEs with a prevalence of approximately 10%. Case study: We retrospect...